{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:04:39Z","timestamp":1793606679594,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.lungcan.2023.107291","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T21:06:44Z","timestamp":1688418404000},"page":"107291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer"],"prefix":"10.1016","volume":"182","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0614-9546","authenticated-orcid":false,"given":"Sheena","family":"Bhalla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farjana J.","family":"Fattah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Macchiaroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Padro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Pogue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Dowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Putnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"McCracken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Micklem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf A.","family":"Brekken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.lungcan.2023.107291_b0005","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","article-title":"Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy","volume":"18","author":"Shepherd","year":"2000","journal-title":"J Clin Oncol."},{"issue":"9944","key":"10.1016\/j.lungcan.2023.107291_b0010","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet."},{"issue":"17","key":"10.1016\/j.lungcan.2023.107291_b0015","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med."},{"issue":"10","key":"10.1016\/j.lungcan.2023.107291_b0020","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1517\/14728222.2010.515980","article-title":"Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors","volume":"14","author":"Linger","year":"2010","journal-title":"Expert Opin Ther Targets."},{"key":"10.1016\/j.lungcan.2023.107291_b0025","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0065-230X(08)00002-X","article-title":"TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer","volume":"100","author":"Linger","year":"2008","journal-title":"Adv Cancer Res."},{"issue":"12","key":"10.1016\/j.lungcan.2023.107291_b0030","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1593\/neo.05640","article-title":"Expression of axl in lung adenocarcinoma and correlation with tumor progression","volume":"7","author":"Shinh","year":"2005","journal-title":"Neoplasia."},{"issue":"4","key":"10.1016\/j.lungcan.2023.107291_b0035","doi-asserted-by":"crossref","first-page":"e0154186","DOI":"10.1371\/journal.pone.0154186","article-title":"Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression","volume":"11","author":"Sato","year":"2016","journal-title":"PLoS One."},{"issue":"S3","key":"10.1016\/j.lungcan.2023.107291_b0040","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1245\/s10434-012-2795-3","article-title":"Higher expression of receptor tyrosine kinase Axl, and differential expression of its ligand, Gas6, predict poor survival in lung adenocarcinoma patients","volume":"20","author":"Ishikawa","year":"2013","journal-title":"Ann Surg Oncol."},{"key":"10.1016\/j.lungcan.2023.107291_b0045","doi-asserted-by":"crossref","unstructured":"Holland SJ, Pan A, Franci C, et al. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res. 2010;70(4):1544-1554.","DOI":"10.1158\/0008-5472.CAN-09-2997"},{"issue":"Supplement 1","key":"10.1016\/j.lungcan.2023.107291_b0050","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1182\/blood-2018-99-120380","article-title":"Final Analysis of the Dose Escalation, Expansion and Biomarker Correlations in the Ph I\/II Trial BGBC003 with the Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed\/Refractory AML and MDS","volume":"132","author":"Loges","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.lungcan.2023.107291_b0055","doi-asserted-by":"crossref","unstructured":"Wilson C, Ye X, Pham T, et al. AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs. Cancer Res. 2014;74(20):5878-5890.","DOI":"10.1158\/0008-5472.CAN-14-1009"},{"issue":"25","key":"10.1016\/j.lungcan.2023.107291_b0060","doi-asserted-by":"crossref","first-page":"41064","DOI":"10.18632\/oncotarget.17026","article-title":"Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer","volume":"8","author":"Lin","year":"2017","journal-title":"Oncotarget."},{"issue":"2","key":"10.1016\/j.lungcan.2023.107291_b0065","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer."},{"issue":"6","key":"10.1016\/j.lungcan.2023.107291_b0070","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/bioinformatics\/bts034","article-title":"The sva package for removing batch effects and other unwanted variation in high-throughput experiments","volume":"28","author":"Leek","year":"2012","journal-title":"Bioinformatics."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107291_b0075","article-title":"Metascape provides a biologist-oriented resource for the analysis of systems-level datasets","volume":"10","author":"Zhou","year":"2019","journal-title":"Nat Commun."},{"key":"10.1016\/j.lungcan.2023.107291_b0080","unstructured":"BerGenBio. Internal population pharmacokinetics report 457-TR-324."},{"key":"10.1016\/j.lungcan.2023.107291_b0085","doi-asserted-by":"crossref","unstructured":"Baker SD, Zhao M, Lee CK, et al. Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin Cancer Res. 2004;10(6):1976-1983.","DOI":"10.1158\/1078-0432.CCR-0842-03"},{"issue":"21","key":"10.1016\/j.lungcan.2023.107291_b0090","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1200\/JCO.22.00912","article-title":"Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A","volume":"40","author":"Reckamp","year":"2022","journal-title":"J Clin Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2023.107291_b0095","doi-asserted-by":"crossref","first-page":"S258","DOI":"10.1016\/j.jtho.2019.08.515","article-title":"MA03.06 Efficacy Results of Selective AXL Inhibitor Bemcentinib with Pembrolizumab Following Chemotherapy in Patients with NSCLC","volume":"14","author":"Felip","year":"2019","journal-title":"J of Thorac Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2023.107291_b0100","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.jtho.2016.04.015","article-title":"Axl Receptor Axis: A New Therapeutic Target in Lung Cancer","volume":"11","author":"Levin","year":"2016","journal-title":"J Thorac Oncol."},{"key":"10.1016\/j.lungcan.2023.107291_b0105","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.3389\/fonc.2019.01049","article-title":"Behind the Wheel of Epithelial Plasticity in KRAS-Driven Cancers","volume":"9","author":"Arner","year":"2019","journal-title":"Front Oncol."},{"key":"10.1016\/j.lungcan.2023.107291_b0110","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.freeradbiomed.2013.09.011","article-title":"Oxidative stress enhances Axl-mediated cell migration through an Akt1\/Rac1-dependent mechanism","volume":"65","author":"Huang","year":"2013","journal-title":"Free Radic Biol Med."},{"issue":"8","key":"10.1016\/j.lungcan.2023.107291_b0115","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/ng.2330","article-title":"Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer","volume":"44","author":"Zhang","year":"2012","journal-title":"Nat Genet."},{"issue":"6","key":"10.1016\/j.lungcan.2023.107291_b0120","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.21037\/tcr.2019.09.61","article-title":"Blockade of AXL activation overcomes acquired resistance to EGFR tyrosine kinase inhibition in non-small cell lung cancer","volume":"8","author":"Wang","year":"2019","journal-title":"Transl Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107291_b0125","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-08074-0","article-title":"AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells","volume":"10","author":"Taniguchi","year":"2019","journal-title":"Nat Commun."},{"issue":"9","key":"10.1016\/j.lungcan.2023.107291_b0130","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1158\/1078-0432.CCR-19-2321","article-title":"ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in","volume":"26","author":"Okura","year":"2020","journal-title":"Clin Cancer Res."},{"issue":"15_suppl","key":"10.1016\/j.lungcan.2023.107291_b0135","doi-asserted-by":"crossref","first-page":"9110","DOI":"10.1200\/JCO.2021.39.15_suppl.9110","article-title":"Ph I\/II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with erlotinib in patients with advanced EGFRm NSCLC: End of trial update","volume":"39","author":"Byers","year":"2021","journal-title":"J Clin Oncol."},{"issue":"52","key":"10.1016\/j.lungcan.2023.107291_b0140","doi-asserted-by":"crossref","first-page":"89761","DOI":"10.18632\/oncotarget.21125","article-title":"Axl inhibition induces the antitumor immune response which can be further potentiated by PD-1 blockade in the mouse cancer models","volume":"8","author":"Guo","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.lungcan.2023.107291_b0145","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.756225","article-title":"Immune Evasion Mechanism and AXL","volume":"11","author":"Son","year":"2021","journal-title":"Front Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2023.107291_b0150","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"Mutations and PD-1 Inhibitor Resistance in","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.lungcan.2023.107291_b0155","article-title":"AXL targeting restores PD-1 blockade sensitivity of","volume":"3","author":"Li","year":"2022","journal-title":"Cell Rep Med."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223008292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500223008292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:06:17Z","timestamp":1759237577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500223008292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":31,"alternative-id":["S0169500223008292"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107291","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107291","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107291"}}